Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Applied Therapeutics (APLT) Total Current Liabilities (2023 - 2025)

Historic Total Current Liabilities for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to $32.9 million.

  • Applied Therapeutics' Total Current Liabilities fell 6675.46% to $32.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.9 million, marking a year-over-year decrease of 6675.46%. This contributed to the annual value of $27.3 million for FY2024, which is 6165.32% down from last year.
  • Per Applied Therapeutics' latest filing, its Total Current Liabilities stood at $32.9 million for Q3 2025, which was down 6675.46% from $17.7 million recorded in Q2 2025.
  • In the past 5 years, Applied Therapeutics' Total Current Liabilities ranged from a high of $99.0 million in Q3 2024 and a low of $17.7 million during Q2 2025
  • Over the past 3 years, Applied Therapeutics' median Total Current Liabilities value was $47.2 million (recorded in 2023), while the average stood at $49.2 million.
  • As far as peak fluctuations go, Applied Therapeutics' Total Current Liabilities skyrocketed by 15233.83% in 2024, and later tumbled by 7858.89% in 2025.
  • Over the past 3 years, Applied Therapeutics' Total Current Liabilities (Quarter) stood at $71.2 million in 2023, then plummeted by 61.65% to $27.3 million in 2024, then increased by 20.54% to $32.9 million in 2025.
  • Its Total Current Liabilities stands at $32.9 million for Q3 2025, versus $17.7 million for Q2 2025 and $18.0 million for Q1 2025.